A Pharmacodynamic Study With Ticagrelor in African American Patients

Phase 4 Completed 50 enrolled AstraZeneca

RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to assess the pharmacodynamic effect of ticagrelor in African American patients with stable coronary artery disease.

Timeline

Start: 2012-03
Primary completion: 2013-09
Completion: 2013-09

Outcome

Met primary endpoint

registry analysis (superiority or other test); Ticagrelor vs Clopidogrel; p <0.001; Mean Difference (Final Values) -183.6 (95% CI -213.9 to -153.3) NCT01523392 ↗

Publications

Waksman R, Maya J, Angiolillo DJ, Carlson GF, Teng R, Caplan RJ, Ferdinand KC. Ticagrelor Versus Clopidogrel in Black Patients With Stable Coronary Artery Disease: Prospective, Randomized, Open-Label, Multiple-Dose, Crossover Pilot Study. Circ Cardiovasc Interv. 2015 Jul;8(7):e002232. doi: 10.1161/CIRCINTERVENTIONS.114.002232.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Clopidogrel	Small molecule	75 mg	—
Subject	Ticagrelor	Small molecule	90 mg	—